A Phase 2 interventional study of Apremilast in Psoriasis, sponsored by Amgen. Completed at 18 sites in 4 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-05-07.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.
Among the 44 studies testing apremilast in Psoriasis, this one is the 30th largest by enrollment, is one of 3 that started in 2015, is one of 10 in phase 2, and was the 16th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:
Syeda Sana Zaman · Sites in Pakistan
Ages 18–60 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
Amgen
Ages 18–60 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Zarmeen Khawar · Sites in Pakistan
Ages 18–65
By country, each count listing its studies:
apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 103 across the 44 interventional studies. Of the 34 that completed or were terminated, 26 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
61 studies in Psoriasis by Amgen: 1 open now, 1 under way, none of them phase 3. Of 60 finished, 35 (58%) have results posted.
Among the 61 studies in Psoriasis by Amgen, this one is the 43rd largest by enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2015, is one of 8 in phase 2, and was the 36th registered.
Amgen’s Psoriasis studies by the year they started, since 2000.
1 of the studies testing apremilast in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07908641AmgenComparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation | 2027-01-10 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing apremilast in Psoriasis, from their registry updates:
Among Amgen’s 61 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, multicenter, open-label study in subjects with moderate to severe plaque psoriasis aged 6 to 17 years, inclusive, intended to assess the safety, tolerability, and PK of apremilast with 2 weeks of oral apremilast treatment followed by a 48-week extension of apremilast treatment. Moderate to severe plaque psoriasis is defined as Psoriasis Area Severity Index (PASI) ≥ 12, Body Surface Area (BSA) ≥ 10%, and static Physician Global Assessment (sPGA) of ≥ 3. The total study duration for each subject will last for up to a total of 107 weeks which includes screening, treatment (including the PK portion of the study and the extension treatment period), two short-term follow-up periods and a long-term follow-up period.
Each subject will undergo a screening period of up to 5 weeks, a treatment period of 2 weeks with PK sample collection, and an extension treatment period of 48 weeks, to allow subjects access to apremilast treatment if medically appropriate (following the completion of the 2 week PK portion). Regardless of when they stop treatment, subjects should complete two post treatment follow-up visits at approximately 4 and 8 weeks after the last dose. All subjects should complete the final follow-up visit at Week 102 or at a timepoint 52 weeks after the last dose of apremilast was taken in subjects who have withdrawn at any time prior to Week 50. At least 32 subjects will be enrolled into this study to provide an adequate PK profile and safety assessment in subjects of different ages and body weight ranges. Subjects will be divided into 2 age groups (adolescents [ages 12 to 17 years, inclusive] and children [ages 6 to 11 years, inclusive]), with at least 16 subjects in each group. Apremilast treatment will start in older and heavier subjects.
Group 1 (ages 12 to 17 years, inclusive; weight ≥ 35 kg)
and an evaluation of these data by the DMC has been completed.
Group 2 (ages 6 to 11 years, inclusive; weight ≥ 15 kg)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have moderate to severe plaque psoriasis at Screening and Baseline as defined by:
At Screening, laboratory values must be within the following ranges:
Exclusion Criteria:
The presence of any of the following will exclude a subject from enrollment:
Having received biologic therapy within 5 terminal half-lives, including but not limited to the following time periods:
Topical therapy within 2 weeks of baseline (including but not limited to topical , topical retinoid or vitamin D analog preparations, tacrolimus, pimecrolimus, or anthralin/dithranol)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apremilast doses of 10-mg, 20-mg or 30-mg tablets have been selected to determine the dose range in adolescents and children with moderate to severe plaque psoriasis. These pediatric dosages are expected to achieve exposures similar to those achieved in adult psoriasis and psoriatic arthritis (PsA) subjects treated with apremilast 30 mg orally twice daily (BID). A staggered, stepwise approach by age range and weight (starting with older and heavier subjects) is considered appropriate for this first-time-in-children study. Doses for younger and lower body weight subjects will be adjusted based on safety and PK data from older and heavier subjects. Subjects will be divided into 2 age groups with at least 16 subjects in each group. Dosing within and between groups will be staggered, based on PK data collected and on a minimum of 2 weeks of safety data.
Drug: Apremilast
Also known as: CC-10004
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
A TEAE is an adverse event with a start date on or after the date of the first dose of apremilast and no later than 28 days after the last dose of apremilast. An adverse event is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. A serious AE is any untoward AE that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization or in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect or constitutes an important medical event. The investigator assessment of severity/intensity of an event was defined as mild, moderate or severe.
Time frame: From first dose of apremilast until 28 days after the last dose; up to 29 July 2019; median treatment duration for adolescents apremilast 20 mg and 30 mg was 50.00 and 50.57 weeks respectively and for children was 50.00 weeks.
Maximum Observed Plasma Concentration (Cmax) of Apremilast
Maximum observed plasma concentration (Cmax) of apremilast. PK parameters were calculated using non-compartmental methods, plasma concentrations and actual blood sampling times from the intensive sampling schedule.
Time frame: For adolescents, a pre-dose sample prior to morning dose and on Day 14 as well as at hours 1, 2, 3, 5, 8 and 12 post dose; for the children, samples were collected 2 hours at predose (prior to morning dose) and at 2, 5 and 12 hours post morning dose.
Time to Maximum Plasma Concentration (Tmax) of Apremilast
Time to maximum observed plasma concentration obtained directly from the observed concentration versus time data. PK parameters were calculated using non-compartmental methods, plasma concentrations and actual blood sampling times from the intensive sampling schedule.
Time frame: For adolescents, a pre-dose sample prior to morning dose and on Day 14 as well as at hours 1, 2, 3, 5, 8 and 12 post dose; for the children, samples were collected 2 hours at predose (prior to morning dose) and at 2, 5 and 12 hours post morning dose.
Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post Dose of Apremilast (AUC0-12)
Area under the plasma concentration-time curve from time zero to the 12 hours post dose was calculated using non-compartmental methods, plasma concentrations and actual blood sampling times from the intensive sampling schedule.
Time frame: For adolescents, a pre-dose sample prior to morning dose and on Day 14 as well as at hours 1, 2, 3, 5, 8 and 12 post dose; for the children, samples were collected 2 hours at predose (prior to morning dose) and at 2, 5 and 12 hours post morning dose.
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration of Apremilast (AUC0-t)
Area under the plasma concentration-time curve from time zero to the last quantifiable time point and was calculated using non-compartmental methods, plasma concentrations and actual blood sampling times from the intensive sampling schedule.
Time frame: For adolescents, a pre-dose sample prior to morning dose and on Day 14 as well as at hours 1, 2, 3, 5, 8 and 12 post dose; for the children, samples were collected 2 hours at predose (prior to morning dose) and at 2, 5 and 12 hours post morning dose.
Apparent Total Plasma Clearance When Dosed Orally (CL/F) for Apremilast
Apparent total plasma clearance (CL/F) of apremilast was calculated using non-compartmental methods, plasma concentrations and actual blood sampling times from the intensive sampling schedule.
Time frame: For adolescents, a pre-dose sample prior to morning dose and on Day 14 as well as at hours 1, 2, 3, 5, 8 and 12 post dose; for the children, samples were collected 2 hours at predose (prior to morning dose) and at 2, 5 and 12 hours post morning dose.
Apparent Total Volume of Distribution When Dosed Orally, Based on Study-State (Vss/F) or in the Terminal Phase (Vz/F)
Apparent total volume of distribution when dosed orally, based on study-state (Vss/F) or in the terminal phase (Vz/F). Pharmacokinetic parameters were calculated using non-compartmental methods, plasma concentrations and actual blood sampling times from the intensive sampling schedule.
Time frame: For adolescents, a pre-dose sample prior to morning dose and on Day 14 as well as at hours 1, 2, 3, 5, 8 and 12 post dose; for the children, samples were collected 2 hours at predose (prior to morning dose) and at 2, 5 and 12 hours post morning dose.
Terminal Phase Elimination Half-Life
Terminal-phase elimination half-life (t ½). PK parameters were calculated using non-compartmental methods, plasma concentrations and actual blood sampling times from the intensive sampling schedule.
Time frame: For adolescents, a pre-dose sample prior to morning dose and on Day 14 as well as at hours 1, 2, 3, 5, 8 and 12 post dose; for the children, samples were collected 2 hours at predose (prior to morning dose) and at 2, 5 and 12 hours post morning dose.
Taste and Acceptability of Apremilast Tablets Using the Faces Likert Scale
Taste and acceptability of the apremilast tablet was assessed using a faces Likert Scale on Day 1, initial dosing. The scale consists of options from 1 (dislike very much, illustrated by a frowning face) to 5 (like very much, illustrated by a smiling face).
Time frame: Day 1
The study was conducted at 11 study centers in 4 countries, including the United States, Canada, Germany and Spain.
| Milestone | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg |
|---|---|---|---|
| Started | 13 | 8 | 21 |
| Pharmacokinetic (pk) population | 12 | 8 | 18 |
| Completed | 8 | 7 | 16 |
| Not completed | 5 | 1 | 5 |
| Withdrew: Adverse event | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 3 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Miscellaneous | 2 | 0 | 0 |
A TEAE is an adverse event with a start date on or after the date of the first dose of apremilast and no later than 28 days after the last dose of apremilast. An adverse event is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. A serious AE is any untoward AE that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization or in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect or constitutes an important medical event. The investigator assessment of severity/intensity of an event was defined as mild, moderate or severe.
| Participants | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg |
|---|---|---|---|
| Any TEAE | 13 | 7 | 20 |
| Any Drug Related TEAE | 11 | 6 | 17 |
| Any Severe TEAE | 1 | 0 | 1 |
| Any Serious TEAE | 0 | 0 | 1 |
| Any Serious Drug-Related TEAE | 0 | 0 | 0 |
| Any TEAE Leading to Drug Interruption | 1 | 0 | 4 |
| Any TEAE Leading to Drug Withdrawal | 0 | 0 | 2 |
| Any TEAE Leading to Death | 0 | 0 | 0 |
Maximum observed plasma concentration (Cmax) of apremilast. PK parameters were calculated using non-compartmental methods, plasma concentrations and actual blood sampling times from the intensive sampling schedule.
| ng/mL | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Apremilast | 274.272 ± 34.3 | 410.929 ± 39.7 | 348.146 ± 47.4 |
Time to maximum observed plasma concentration obtained directly from the observed concentration versus time data. PK parameters were calculated using non-compartmental methods, plasma concentrations and actual blood sampling times from the intensive sampling schedule.
| hours | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg |
|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Apremilast | 2.467 (1.00 to 3.00) | 3.000 (1.00 to 5.00) | 2.000 (1.90 to 5.00) |
Area under the plasma concentration-time curve from time zero to the 12 hours post dose was calculated using non-compartmental methods, plasma concentrations and actual blood sampling times from the intensive sampling schedule.
| ng*h/mL | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post Dose of Apremilast (AUC0-12) | 1799.717 ± 36.0 | 2901.795 ± 41.2 | 2544.874 ± 40.8 |
Area under the plasma concentration-time curve from time zero to the last quantifiable time point and was calculated using non-compartmental methods, plasma concentrations and actual blood sampling times from the intensive sampling schedule.
| ng*h/mL | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration of Apremilast (AUC0-t) | 1794.815 ± 35.9 | 2900.472 ± 41.4 | 2367.641 ± 50.2 |
Apparent total plasma clearance (CL/F) of apremilast was calculated using non-compartmental methods, plasma concentrations and actual blood sampling times from the intensive sampling schedule.
| Liters/hour | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg |
|---|---|---|---|
| Apparent Total Plasma Clearance When Dosed Orally (CL/F) for Apremilast | 11.113 ± 36.0 | 10.338 ± 41.2 | 7.859 ± 40.8 |
Apparent total volume of distribution when dosed orally, based on study-state (Vss/F) or in the terminal phase (Vz/F). Pharmacokinetic parameters were calculated using non-compartmental methods, plasma concentrations and actual blood sampling times from the intensive sampling schedule.
| Liters | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg |
|---|---|---|---|
| Apparent Total Volume of Distribution When Dosed Orally, Based on Study-State (Vss/F) or in the Terminal Phase (Vz/F) | 86.870 ± 56.1 | 101.049 ± 31.6 | 55.126 ± 51.2 |
Taste and acceptability of the apremilast tablet was assessed using a faces Likert Scale on Day 1, initial dosing. The scale consists of options from 1 (dislike very much, illustrated by a frowning face) to 5 (like very much, illustrated by a smiling face).
| Participants | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg |
|---|---|---|---|
| 1 (Dislike Very Much) | 0 | 0 | 3 |
| 2 (Dislike a Little) | 1 | 0 | 1 |
| 3 (Not Sure) | 5 | 4 | 3 |
| 4 (Like a Little) | 1 | 1 | 4 |
| 5 (Like Very Much) | 6 | 3 | 10 |
Terminal-phase elimination half-life (t ½). PK parameters were calculated using non-compartmental methods, plasma concentrations and actual blood sampling times from the intensive sampling schedule.
| hours | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg |
|---|---|---|---|
| Terminal Phase Elimination Half-Life | 5.418 ± 43.1 | 6.775 ± 50.3 | 4.862 ± 30.2 |
Collected over From first dose of apremilast until 28 days after the last dose; up to 198 weeks; median treatment duration for adolescents apremilast 20 mg and 30 mg was 50.00 and 50.57 weeks respectively and for children was 50.00 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 Adolescents: Apremilast 20 mg | 0/13 (0%) | 0/13 (0%) | 13/13 (100%) |
| Group 1 Adolescents: Apremilast 30 mg | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Group 2 Children: Apremilast 20 mg | 0/21 (0%) | 1/21 (4.8%) | 19/21 (90.5%) |
| Event | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg |
|---|---|---|---|
| SyncopeNervous system disorders | 0/13 | 0/8 | 1/21 |
| Event | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg |
|---|---|---|---|
| NauseaGastrointestinal disorders | 8/13 | 4/8 | 10/21 |
| HeadacheNervous system disorders | 7/13 | 1/8 | 11/21 |
| Abdominal painGastrointestinal disorders | 6/13 | 1/8 | 11/21 |
| DiarrhoeaGastrointestinal disorders | 6/13 | 4/8 | 5/21 |
| NasopharyngitisInfections and infestations | 6/13 | 3/8 | 7/21 |
| VomitingGastrointestinal disorders | 4/13 | 1/8 | 8/21 |
| Urinary tract infectionInfections and infestations | 1/13 | 2/8 | 0/21 |
| GastroenteritisInfections and infestations | 2/13 | 1/8 | 5/21 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/13 | 1/8 | 2/21 |
| Abdominal pain upperGastrointestinal disorders | 2/13 | 1/8 | 4/21 |
The Safety Population consisted of all participants who were enrolled and received at least 1 dose of apremilast.
| Age, Continuous(Years) | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg | Total |
|---|---|---|---|---|
| Mean | 13.8 ± 1.77 | 14.8 ± 2.05 | 9.3 ± 1.35 | 11.8 ± 2.95 |
| Age, Customized(Participants) | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg | Total |
|---|---|---|---|---|
| 6 to 11 years | 0 | 0 | 21 | 21 |
| 12 to 17 years | 13 | 8 | 0 | 21 |
| Sex: Female, Male(Participants) | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg | Total |
|---|---|---|---|---|
| Female | 9 | 1 | 13 | 23 |
| Male | 4 | 7 | 8 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 5 | 9 |
| Not Hispanic or Latino | 12 | 5 | 16 | 33 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 2 | 0 | 2 | 4 |
| Black or African American | 0 | 0 | 2 | 2 |
| Native Hawaiian or other Pacific Islander | 0 | 1 | 0 | 1 |
| White or Caucasian | 10 | 6 | 16 | 32 |
| Other | 1 | 1 | 1 | 3 |
| Baseline Weight Category (kg)(Participants) | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg | Total |
|---|---|---|---|---|
| < 15 kg | 0 | 0 | 0 | 0 |
| ≥ 15 - < 35 kg | 0 | 0 | 13 | 13 |
| ≥ 35 - < 50 kg | 3 | 0 | 4 | 7 |
| ≥ 50 - < 70 kg | 10 | 0 | 4 | 14 |
| ≥ 70 kg | 0 | 8 | 0 | 8 |
| Duration of Plaque Psoriasis(Years) | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg | Total |
|---|---|---|---|---|
| Mean | 7.41 ± 3.190 | 6.96 ± 4.057 | 2.75 ± 2.057 | 4.99 ± 3.611 |
| Psoriasis Area Severity Index (PASI)(Units on a scale) | Group 1 Adolescents: Apremilast 20 mg | Group 1 Adolescents: Apremilast 30 mg | Group 2 Children: Apremilast 20 mg | Total |
|---|---|---|---|---|
| Mean | 18.78 ± 11.693 | 15.65 ± 3.430 | 18.09 ± 6.144 | 17.84 ± 7.854 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Oct 2015 to primary completion in Sep 2017, 22 months.
Results were first posted in Sep 2018, 1 year after primary completion.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 22 months is above that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast